ReviewInflammopharmacology2026
Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and therapeutic innovations.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Ovarian cancer, one of the most prevalent and formidable malignant tumours within the female reproductive system, poses a grave threat to women's health and lives. Although the current standard-of-care treatments-including cytoreductive surgery and platinum-based chemotherapy, supplemented by maintenance therapy with anti-angiogenic agents and poly (ADP-ribose) polymerase (PARP) inhibitors, can alleviate the disease to a certain extent, they face significant limitations, such as resistance to chemotherapeutic drugs, toxicity to normal tissues, and recurrence of the tumour. In contrast, natural killer (NK) cells, as an important part of the body's immune system, have anti-tumour activities, and their interaction with ovarian cancer cells to kill ovarian cancer cells brings new hope for cell therapy. The aim of this paper is to summarize the mechanisms involved in NK cells in ovarian cancer treatment, the current status of clinical applications, and new research strategies in the future, with the aim of providing a reference for the development of research and clinical practice in this field.
Indexed as
Identifiers
42753071What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.